相关实验视频
Updated: Feb 17, 2026

05:17
Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
Published on: April 18, 2025
967
分子探针:从Aβ成像到阿尔茨海默病的光疗
Zhiyong Jiang1, Huizhe Wang1, Jiang Yu1
1Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital/Harvard Medical School, Charlestown, Boston, Massachusetts 02129, United States.
Accounts of chemical research
|February 16, 2026
概括
研究人员开发了用于阿尔茨海默病 (AD) 成像和治疗的新型小分子探针. 这些探针能够对粉样β (Aβ) 种类进行敏感检测,方便体内全脑成像和监测治疗疗效.
科学领域:
- 化学 化学 化学
- 化学生物学 化学生物学
- 神经科学是一个神经科学.
背景情况:
- 阿尔茨海默病 (AD) 的特征是氨基酸β (Aβ) 沉积.
- 开发敏感的Aβ成像探针对于AD诊断和治疗至关重要.
- 小分子光学探针为体内和Aβ的高分辨率成像提供了潜力.
研究的目的:
- 介绍关于基于小分子的Aβ成像探针和治疗方法的三部曲研究.
- 突出Aβ成像的进步,从检测到分子机制和药物发现.
- 为未来的研究提供对Aβ探测器设计策略的见解.
主要方法:
- 在AD小鼠中开发近红外光 (NIRF) 探针 (CRANAD-Xs) 用于选择性Aβ物种成像.
- 探索化学发光探针 (ADLumin-Xs) 用于深层组织成像和3D全脑Aβ可视化.
- 研究分子光 (化学发光/生物发光) 用于光学应用,包括用于Aβ积累的光疗.
主要成果:
- 克拉纳德-Xs能够在体内对各种Aβ物种进行成像,并对治疗疗效进行纵向监测.
- ADLumin-Xs实现了高信号噪声比,深层组织透,以及第一个体内3D全脑化学发光成像Aβ.
- 分子光疗证明了在AD小鼠中减缓Aβ积累的潜力.
结论:
- 小分子探针是AD研究中Aβ成像和治疗监测的有效工具.
- 化学发光探测器克服了NIRF成像的局限性,使得Aβ可视化更深入,更精确.
- 分子光对阿尔茨海默氏病治疗中的超神应用有前途.
相关概念视频
Alzheimer's Disease: Treatment
994
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
994
Alzheimer's Disease: Overview
1.8K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.8K

